Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study
Meletios A Dimopoulos, Peter M. Voorhees, Fredrik Schjesvold, Yaël C. Cohen, Vânia Hungria, Irwindeep Sandhu, Jindriska Lindsay, Ross Baker, Kenshi Suzuki, Hiroshi Kosugi, Mark‐David Levin, Meral Beksac, Keith Stockerl‐Goldstein, Albert Oriol, Gábor Mikala, Gonzalo Garate, Koen Theunissen, Ivan Špıčka, Anne K. Mylin, Sara Galimberti, Katarina Uttervall, Bartosz Michal Pula, Eva Medvedova, Andrew J. Cowan, Philippe Moreau, María‐Victoria Mateos, Hartmut Goldschmidt, Tahamtan Ahmadi, Linlin Sha, Els Rousseau, Liang Li, Robyn M. Dennis, Robin Carson, S. Vincent Rajkumar (2024). Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study. , 144(Supplement 1), DOI: https://doi.org/10.1182/blood-2024-201057.
Article24 days agoPhase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study
Meletios A Dimopoulos, Peter M. Voorhees, Fredrik Schjesvold, Yaël C. Cohen, Vânia Hungria, Irwindeep Sandhu, Jindriska Lindsay, Ross Baker, Kenshi Suzuki, Hiroshi Kosugi, Mark‐David Levin, Meral Beksac, Keith Stockerl‐Goldstein, Albert Oriol, Gábor Mikala, Gonzalo Garate, Koen Theunissen, Ivan Špıčka, Anne K. Mylin, Sara Galimberti, Katarina Uttervall, Bartosz Michal Pula, Eva Medvedova, Andrew J. Cowan, Philippe Moreau, María‐Victoria Mateos, Hartmut Goldschmidt, Tahamtan Ahmadi, Linlin Sha, Els Rousseau, Liang Li, Robyn M. Dennis, Robin Carson, S. Vincent Rajkumar (2024). Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study. , 144(Supplement 1), DOI: https://doi.org/10.1182/blood-2024-201057.
Article24 days agoP13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?
Rakesh Popat, Ashraf Badros, Seema Kumar, Paula Rodríguez‐Otero, Alan R. Cohen, Salomon Manier, Peter M. Voorhees, Francesca Gay, Robert M. Rifkin, T. Martin, Ajai Chari, Katja Weisel, Asim V. Farooq, Bennie H. Jeng, Wee Joo Chng, H Lee, J. G. Berdeja, Vinay Jadhav, A Tosolini, L Eliason, A Palumbo, Meletios A Dimopoulos, Sagar Lonial, S. Trudel, PG Richardson, Evangelos Terpos (2022). P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?. , 6, DOI: https://doi.org/10.1097/01.hs9.0000829624.40467.0d.
Article24 days agoSubcutaneous daratumumab (DARA SC) versus active monitoring in patients (pts) with high-risk smoldering multiple myeloma (SMM): Randomized, open-label, phase 3 AQUILA study.
Meletios A Dimopoulos, Peter M. Voorhees, Hartmut Goldschmidt, Ross Baker, Yingqi Shi, Els Rousseau, Robyn Monet Dennis, Robin Carson, S. Vincent Rajkumar (2022). Subcutaneous daratumumab (DARA SC) versus active monitoring in patients (pts) with high-risk smoldering multiple myeloma (SMM): Randomized, open-label, phase 3 AQUILA study.. , 40(16_suppl), DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.tps8075.
Article24 days agoCan Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?
Rakesh Popat, Ashraf Badros, Shaji Kumar, Paula Rodríguez‐Otero, Adam D. Cohen, Salomon Manier, Peter M. Voorhees, Francesca Gay, Robert M. Rifkin, Thomas G. Martin, Ajai Chari, Katja Weisel, Asim V. Farooq, Bennie H. Jeng, Wee Joo Chng, Hans C. Lee, Jesús G. Berdeja, Vinay Jadhav, Alessandra Tosolini, Laurie Eliason, Antonio Palumbo, Meletios A Dimopoulos, Sagar Lonial, Suzanne Trudel, Paul G. Richardson, Evangelos Terpos (2021). Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?. , 138(Supplement 1), DOI: https://doi.org/10.1182/blood-2021-152681.
Article24 days ago